糖尿病临床研究

　　[摘要] 目的 观察应用胰岛素联合口服降血糖药物(OADs)血糖控制不佳的T2DM患者加用利拉鲁肽后，胰岛β细胞功能及血糖波动的变化。 方法 40例T2DM患者(HbA1c>7.0%)在胰岛素联用OADs的基础上加用利拉鲁肽治疗12周，观察治疗前后血糖、HbA1c、胰岛β细胞功能指数(HOMA-β)及血糖波动的变化。 结果 加用利拉鲁肽治疗12周后，HbA1c[(8.21±2.65)% vs(7.16±0.8)%]、平均血糖波动幅度(MAGE)[(3.98±0.52)vs(1.52±0.27)mmol/L]、日间血糖平均绝对差(MODD)[(1.29±0.34)vs(0.45±0.13)mmol/L]下降(P<0.05);FC-P[(1.16±0.75)vs(2.87±1.02)ng/ml]、2 hC-P[(2.28±1.23)vs(4.16±0.98)ng/ml]及HOMA-β[(3.6±0.7)vs(4.8±0.9)]升高(P<0.05)。 结论 对于胰岛素联合OADs血糖控制不佳的T2DM患者，加用利拉鲁肽可有效降糖、平稳降糖，改善胰岛β细胞功能。

　　[关键词] 利拉鲁肽;糖尿病，2型;胰岛β细胞功能;血糖波动

　　Effects of Liraglutide on islet beta cell function and blood glucose fluctuation in type 2 diabetic patients with unsatisfactory glycemic control ZHANG Jie, ZHAO Yuan-yuan, ZHOU Hui-min,et al.Department of Endocrinology, The First Hospital of Hebei Medical University, Shijiazhuang 050031, China

　　Corresponding author:ZHANG Xue-lian,E-mail: zhangxuelian66@sina.com

　　[Abstract] Objective To evaluate the change of islet beta cell function and blood glucose fluctuation after Liraglutide combined treatment in type 2 diabetic patients with unsatisfactory glycemic control using insulin and oral antidiabetic drugs(OADs). Methods A total of 40 type 2 diabetic patients with unsatisfactory glycemic control using insulin and OADs were involved the study. All the subjects were treated with Liraglutide as add-on therapy for 12 weeks. Blood glucose,HbA1c, homeostasis model of beta cell function index (HOMA-β) and blood glucose fluctuation index were measured before and after treatment. Results After adding Liraglutide, HbA1c[(8.21±2.65)% vs(7.16±0.8)%], MAGE[(3.98±0.52)vs(1.52±0.27)mmol/L] and MODD[(1.29±0.34)vs(0.45±0.13)mmol/L] were significantly decreased. Fasting C-peptide[(1.16±0.75)vs(2.87±1.02)ng/ml], 2 hC-peptide[(2.28±1.23)vs(4.16±0.98)ng/ml] and HOMA-β[(3.6±0.7)vs(4.8±0.9)]were significantly increased (P<0.05). Conclusion Liraglutide can effectively controlled glucose, reduced blood glucose fluctuation, and improve islet beta cell function in pooly controlled type 2 diabetes with insulin and OADs.

　　[Key words] Liraglutideon;Diabetes mellitus,type 2;Islet beta cell function;Blood glucose fluctuation